An official website of the United States government
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
Trial Status: administratively complete
ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy
and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with
pembrolizumab in the first-line setting. The population will consist of adults with PD-L1
positive recurrent or metastatic HNSCC.
Inclusion Criteria
Histological or cytological confirmation of recurrent or metastatic HNSCC
Measurable disease as defined by RECIST v1.1
PD-L1 positive
Exclusion Criteria
Diagnosis of recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology; or salivary gland or non-squamous histologies (e.g. mucosal melanoma)
Disease amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Prior systemic anti-cancer therapy (use of chemotherapeutic agents, targeted small molecules, immunotherapy, or monoclonal antibodies) for the treatment of recurrent or metastatic HNSCC
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03937141.
